Moderna rises, study shows its mRNA flu vaccine outperforms standard shot

Moderna

07/05/2026 15:22

Updates

** Moderna MRNA.O shares rise 1.8% to $49.66

** The vaccine maker late on Wednesday reported results from a late-stage study that showed its mRNA-based seasonal flu vaccine worked better than conventional flu shots

** Moderna's flu shot was 26.6% more effective than an approved standard-dose GSK GSK.L flu shot, exceeding the study's main goal

** U.S. FDA is reviewing the vaccine after rejecting MRNA's initial application; decision expected by August 5

** Separately, Evercore ISI analyst Corey Kasimov said, "As a heavily retail-trafficked name, MRNA tends to trade on outbreak headlines well beyond the underlying commercial implications"

** Moderna signed a research agreement in 2023 with Korea University to develop a vaccine for hantavirus

** With regards to current headlines, we see no meaningful revenue opportunity. Hantavirus is a low-incidence, structurally small market, and we view any potential outsized moves as sentiment-driven, not fundamental - Evercore

** Including session moves, stock up 72% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))